Freedom Investment Management’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Freedom Investment Management’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-11,796	Closed	-$41K	–	1193
2018 Q1	$41K	Buy	11,796 +196	+2%	+$831	﹤0.01%	1106
2017 Q4	$36K	Buy	11,600 +168	+1%	+$807	﹤0.01%	1125
2017 Q3	$80K	Sell	11,432 -664	-5%	-$5.32K	﹤0.01%	1076
2017 Q2	$112K	Buy	12,096 +15	+0.1%	+$144	0.01%	1029
2017 Q1	$130K	Sell	12,081 -1,648	-12%	-$16.8K	0.01%	1012
2016 Q4	$116K	Buy	+13,729	New	+$122K	0.01%	946

Other funds holding NVLN

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Freedom Investment Management's NVLN Position: Q2 2018 in Review

Freedom Investment Management sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2018, closing a stake of 11,796 shares — an estimated $41K sold.

Freedom Investment Management first reported a position in NVLN in Q4 2016 and held it in 6 quarters. The position peaked at $130K in Q1 2017. 53 funds tracked by Wall St. Rank hold NVLN as of Q2 2018.

Freedom Investment Management reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2018 after selling out during the quarter.
Freedom Investment Management sold 11,796 Novelion Therapeutics Inc. Common Shares shares in Q2 2018, an estimated $41K.
Freedom Investment Management first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 6 quarters.
Freedom Investment Management's Novelion Therapeutics Inc. Common Shares position peaked at $130K in Q1 2017.
53 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2018.

Based on Freedom Investment Management's 13F filing for Q2 2018, filed 27 Jul 2018.